These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10372838)

  • 21. Pathogenesis of parathyroid hyperplasia in renal failure.
    Cozzolino M; Brancaccio D; Gallieni M; Galassi A; Slatopolsky E; Dusso A
    J Nephrol; 2005; 18(1):5-8. PubMed ID: 15772917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of parathyroid intervention in the management of secondary hyperparathyroidism.
    Fukagawa M; Nakanishi S
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii23-6. PubMed ID: 12771294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth.
    Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
    Nephrol Dial Transplant; 2008 Nov; 23(11):3662-9. PubMed ID: 18515308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current treatment options in secondary renal hyperparathyroidism.
    Reichel H
    Nephrol Dial Transplant; 2006 Jan; 21(1):23-8. PubMed ID: 16144852
    [No Abstract]   [Full Text] [Related]  

  • 25. Calcium and phosphorus metabolism in chronic uremia.
    Fiaschi E; Mioni G; Maschio G; D'Angelo A; Ossi E
    Nephron; 1975; 14(2):163-80. PubMed ID: 1093055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease].
    Cozzolino M; Butti A; Chiarelli G; Rocca-Rey L; Santagostino G; Gallieni M; Brancaccio D
    Ital Heart J Suppl; 2005 Jan; 6(1):25-8. PubMed ID: 15776728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
    Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
    Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parathyroid acidosis in uraemia.
    Muldowney FP; Donohoe JF; Carroll DV; Powell D; Freaney R
    Q J Med; 1972 Jul; 41(163):321-42. PubMed ID: 5072056
    [No Abstract]   [Full Text] [Related]  

  • 29. Highly concentrated calcitriol and its analogues induce apoptosis of parathyroid cells and regression of the hyperplastic gland--study in rats.
    Shiizaki K; Hatamura I; Negi S; Sakaguchi T; Saji F; Imazeki I; Kusano E; Shigematsu T; Akizawa T
    Nephrol Dial Transplant; 2008 May; 23(5):1529-36. PubMed ID: 18156462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of alkaline calcium salts as phosphate binder in uremic patients.
    Fournier A; Morinière P; Ben Hamida F; el Esjer N; Shenovda M; Ghazali A; Bouzernidj M; Achard JM; Westeel PF
    Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of direct injection of calcitriol into the parathyroid glands in uraemic patients with moderate to severe secondary hyperparathyroidism.
    Nakanishi S; Yano S; Nomura R; Tsukamoto T; Shimizu Y; Shin J; Fukagawa M
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii47-9. PubMed ID: 12771300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcitriol pulse therapy and histology of parathyroid glands in hemodialysis patients.
    Lomonte C; Martino R; Selvaggiolo M; Bona RM; Cazzato F; Milano R; Chiarulli G; Basile C
    J Nephrol; 2003; 16(5):716-20. PubMed ID: 14733419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of secondary hyperparathyroidism by vitamin D derivatives.
    Drüeke TB
    Am J Kidney Dis; 2001 Jan; 37(1 Suppl 2):S58-61. PubMed ID: 11158863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenesis and medical treatment of secondary hyperparathyroidism.
    Fukagawa M; Kurokawa K
    Semin Surg Oncol; 1997; 13(2):73-7. PubMed ID: 9088062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphate binders for control of phosphate retention in chronic renal failure.
    Loghman-Adham M
    Pediatr Nephrol; 1999 Oct; 13(8):701-8. PubMed ID: 10502131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Oral calcimimetics on secondary hyperparathyroidism of uremia.].
    Imanishi Y
    Clin Calcium; 2017; 27(4):561-566. PubMed ID: 28336833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parathyroid-specific epidermal growth factor-receptor inactivation prevents uremia-induced parathyroid hyperplasia in mice.
    Arcidiacono MV; Yang J; Fernandez E; Dusso A
    Nephrol Dial Transplant; 2015 Mar; 30(3):434-40. PubMed ID: 25324357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current medical management of secondary hyperparathyroidism.
    Yudd M; Llach F
    Am J Med Sci; 2000 Aug; 320(2):100-6. PubMed ID: 10981484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
    Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
    Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.